We hear the refrain again this year from and about Democrats’ chances to retake the Senate: “It’s a bad map.” It was a bad ...

Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...

Adults with type 2 diabetes and cancer who used a GLP-1 had a lower risk for death and hospitalization compared with adults ...

Industry Trends and Global Forecasts, Till 2035" report has been added to ResearchAndMarkets.com's offering. The global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to ...

Benefits of GLP-1 RAs were consistent across age groups and BMI categories, with semaglutide showing significant efficacy. These results were presented during the press briefing ahead of the 2026 ...

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device ...

This story appears in the February 2013 issue of National Geographic magazine. Michael decided to go for a swim. He was on vacation with his family in Guerrero, Mexico, and it was hotter than blazes.

Researchers have found in a new study that adults with type 2 diabetes and cancer who used GLP-1 receptor agonists had a ...

Cutaneous adverse events associated with GLP-1 receptor agonists are uncommon but vary by agent, a study of FDA data shows.

The GLP-1 market is primed for substantial growth due to rising obesity and diabetes rates. Opportunities lie in expanding drug applications beyond diabetes, focusing on weight management in ...